Journal
MULTIPLE SCLEROSIS JOURNAL
Volume 10, Issue 2, Pages 158-164Publisher
SAGE PUBLICATIONS LTD
DOI: 10.1191/1352458504ms1009oa
Keywords
cannabinoid; cannabinoid receptor 1 and 2; experimental autoimmune encephalomyelitis; leukocyte/endothelial interaction; multiple sclerosis
Categories
Ask authors/readers for more resources
Multiple sclerosis (MS) is the most common of the immune demyelinating disorders of the central nervous system (CNS). Leukocyte/ endothelial interactions are important steps in the progression of the disease and substances that interfere with these activities have been evaluated as potential therapeutic agents. Cannabinoid receptor agonists have been shown to downregulate immune responses and there is preliminary evidence that they may slow the progress of MS. The purpose of this investigation was to determine how cannabinoid receptor agonists interfere with leukocyte rolling and adhesion. This was investigated in an experimental auto immune encephalomyelitis (EAE) model using six to eight week old C57BL/6 mice. Mouse myelin oligodendrocyte protein and per tussis toxin were used to induce EAE. WIN 55212-2, CB1 and C B2 antagonist were given. By use of in vivo intravital microscopy, leukocyte/endothelial interactions were evaluated via a cranial window implanted two days before. The results demonstrated that EAE increases leukocyte rolling and firm adhesion in the brain, and that this increased leukocyte/endothelial interaction can be attenuated by administration of WIN 55212-2. Fur thermo re, use of the selective antagonists for the CB1 receptor ( SR 141716A) and the CB2 receptor (SR144528) in this study demonstrated that the cannabinoid's inhibitory effects on leukocyte/endothelial interactions can be mediated by activating CB2 receptor.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available